Mirum announces preliminary 2023 net product sales of $178-180M; LIVMARLI sales up 89% YoY

Mirum Pharmaceuticals, Inc.

2023-FY EPS reported -$4.00 revenue$186,374,000

Preliminary 2023 total revenue $186-188M; net product sales $178-180M.
LIVMARLI net product sales $141-143M, ~89% YoY growth.
Q4 2023 net product sales $69-71M (LIVMARLI $41-43M; CHOLBAM & CHENODAL ~$28M).
FDA PDUFA for LIVMARLI in PFIC on March 13, 2024; NDA submission for CHENODAL in CTX in H1 2024.
Appointed Eric Bjerkholt as CFO; company fully financed with strong balance sheet.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Mirum Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $186-188 million.

Period: the fiscal year ended December 31, 2023
Revenue: $186-188 million
Result: preliminary results

Exact text from the filing

Report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates - $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected

View on SEC.gov

Browse all earnings releases →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-003965

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.